GSK Quarterly Turnover Beats Estimates on Specialty Drug Growth

what happened

U.K. drugmaker GSK reported higher third-quarter sales, driven by its specialty medicines business. According to Dow Jones Newswires, turnover reached 8.89 billion pounds ($11.83 billion), up 4% from a year earlier. Excluding currency changes, the increase was 5%.

Analysts had expected turnover of 8.84 billion pounds, based on consensus figures supplied by the company. Growth in specialty drugs more than offset lower vaccine revenue and flat performance in general medicines.

Pretax profit fell to 1.94 billion pounds from 2.46 billion a year earlier, and net profit dropped to 1.54 billion pounds from 2.01 billion. Excluding exceptional items and currency effects, core operating profit rose 5% to 3.08 billion pounds, above the 2.93 billion pounds analysts had forecast. The company reaffirmed its full-year outlook.

why it matters

For investors, the key takeaway is the beat versus consensus on both turnover and core profit, combined with an unchanged full-year outlook. This supports interest in GSK shares, although the decline in net profit and weakness in vaccines remain pressure points. The company also reiterated its goal of sales above 40 billion pounds by 2031.

market impact

GSK shares: turnover and core profit above forecasts support the stock

• ▲GSK shares pressure up — turnover and core profit above consensus with an unchanged full-year outlook

tags

instruments